The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 20, 2018

Filed:

Nov. 25, 2015
Applicants:

Ubivac, Llc, Portland, OR (US);

Providence Health & Services-oregon, Portland, OR (US);

Inventors:

Traci Hilton, Portland, OR (US);

Sandra Aung, Solana Beach, CA (US);

Rieneke van de Ven, Den Haang, NL;

Christopher Paustian, Portland, OR (US);

Tarsem Moudgil, Beaverton, OR (US);

Christopher Dubay, Portland, OR (US);

Christopher Twitty, Solana Beach, CA (US);

Hong-Ming Hu, Portland, OR (US);

Bernard A. Fox, Portland, OR (US);

Assignees:

UbiVac, LLC, Portland, OR (US);

Providence Health & Services-Oregon, Portland, OR (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12Q 1/68 (2006.01); G01N 33/50 (2006.01); A61K 39/00 (2006.01); A61K 39/39 (2006.01);
U.S. Cl.
CPC ...
C12Q 1/6886 (2013.01); A61K 39/0011 (2013.01); A61K 39/39 (2013.01); G01N 33/505 (2013.01); G01N 33/5023 (2013.01); G01N 33/5047 (2013.01); A61K 2039/55522 (2013.01); A61K 2039/55561 (2013.01); C12Q 2600/136 (2013.01); C12Q 2600/158 (2013.01); G01N 2500/10 (2013.01);
Abstract

A method is presented for screening cells that produce allogeneic autophagosome enriched compositions able to induce expression of a selective marker on a subpopulation of peripheral blood mononuclear cells, the method comprising contacting a cell with a proteasome inhibitor, contacting the cell with a lysosome inhibitor, harvesting the resulting autophagosomes, determining a molecular signature of the harvested autophagosomes, and selecting cells that divert one or more Toll-like receptor agonist and/or one or more molecular chaperones to the harvested autophagosomes. By screening for cells that divert one or more Toll-like receptor agonist and/or one or more molecular chaperones to the harvested autophagosomes, enriched populations of autophagosomes may be generated which may illicit a specific immune response against numerous cancer types. In this way, an allogeneic, off-the-shelf cancer vaccine may be produced and made available to be administered in order to stimulate a targeted immune response in patients bearing different tumor types.


Find Patent Forward Citations

Loading…